FDA Declines Approval for Disc Medicine's Rare Disease Therapy
The FDA has declined approval for Disc Medicine's rare disease therapy, which was previously associated with the commissioner's voucher program. The rejection marks a setback for the company's efforts to bring the treatment to market.
The U.S. Food and Drug Administration (FDA) has declined approval for a rare disease therapy developed by Disc Medicine. The decision affects a treatment that had previously been associated with the agency's commissioner's voucher program, which is designed to incentivize the development of therapies for rare pediatric diseases.
Disc Medicine had sought FDA approval for its therapy aimed at addressing an unspecified rare condition. The company was among early recipients of the commissioner's voucher, a mechanism intended to encourage pharmaceutical companies to invest in treatments for underserved patient populations. The rejection marks a setback in Disc Medicine's efforts to bring this particular therapy to market. Further details regarding the FDA's reasoning behind the decision or next steps from Disc Medicine have not been disclosed at this time.